unitybiotechnology.com (UBX) - EV/EBITDA Multiple
Unity Biotechnology management maintains transparency regarding the stages of ophthalmological trials while remaining dependent on external financing. The price trend based on the EV/EBITDA metric is . The business focuses on developing senolytics to combat tissue aging in the eyes and joints. The primary growth drivers are the efficacy of UBX1325 and potential agreements with major pharmaceutical behemoths.
Analytical breakdowns for unitybiotechnology.com (UBX)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Unity Biotechnology|UBX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Unity Biotechnology, Inc.|UBX - Company Cumulative Debt|Debts to Book Capitalization Unity Biotechnology, Inc|UBX - Company Long-Term Liabilities|Company Short-Term Debts Unity Biotechnology|Quick Liquidity unitybiotechnology.com
- financial results and valuation multiples details:
UBX - Company Profit|Expected Profit Unity Biotechnology|UBX - Market Cap to Earnings|Future Price to Earnings Unity Biotechnology|UBX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc|UBX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Unity Biotechnology|UBX - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months unitybiotechnology.com|UBX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Unity Biotechnology
Initial company analysis:Unity Bio UBX
For Unity Biotechnology (UBX), which monetizes patents for the removal of senescent cells, aligning market value with operational efficiency is critical. This multiple measures the total enterprise value, including debt, relative to earnings before interest, taxes, depreciation, and amortization, thereby determining the asset's real price. The trend of the company's EV/EBITDA ratio allows for an assessment of how market expectations for innovative therapy align with the issuer's current financial stability.
Competitors of Unity Biotechnology (UBX)
tempus.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation QGEN|Ionis Pharmaceuticals - EV/EBITDA Multiple|RGEN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNA: EV/EBITDA Multiple|CRSP - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|Company Value to EBITDA Ultragenyx Corp RARE|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|10x Genomics Inc (TXG) - Company Value to EBITDA|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS: EV/EBITDA Multiple|wavelifesciences.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Enterprise Value to Operating Income Before Depreciation SION (Sionna Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|TSHA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|meiragtx.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Solid Biosciences Inc|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple PacBio Corp PACB|Enterprise Value to EBITDA Ratio BNTC|Company Value to EBITDA designtx.com DSGN|Enterprise Value to EBITDA Ratio RCKT (Rocket Pharmaceuticals, Inc.)|EV/EBITDA Multiple 4DMT (FDMT)|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|EDIT: Enterprise Value to EBITDA Ratio|SLN (silence-therapeutics.com) - Enterprise Value to Operating Income Before Depreciation|PRQR: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology Inc)|EV/EBITDA Multiple MGX|EV/EBITDA Multiple precisionbiosciences.com (DTIL)|Generation Bio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Boundless Bio Inc. BOLD|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNN (Imunon, Inc.) - Enterprise Value to Operating Income Before Depreciation|PHIO: EV/EBITDA Multiple|MBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RNAZ|BNGO (Bionano) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio APDN (Applied DNA)|BLUE - Company Value to EBITDA|ImmunoPrecise Antibodies Ltd. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OMGA|Singular Genomics - EV/EBITDA Multiple|RGLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SYRS: EV/EBITDA Multiple|TBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TRACON Pharmaceuticals
